Why the study?
Older patients with degenerative cervical myelopathy often have multiple comorbidities and polypharmacy, prompting investigation into medication use, characteristics of hyperpolypharmacy, and its impact on postoperative outcomes.
Does hyperpolypharmacy impact preoperative symptoms and postoperative outcomes in older patients undergoing surgery for degenerative cervical myelopathy?
Does hyperpolypharmacy impact preoperative symptoms and postoperative outcomes in older patients undergoing surgery for degenerative cervical myelopathy?
Older patients with degenerative cervical myelopathy and hyperpolypharmacy have worse preoperative symptoms and lack significant quality of life improvements 1 year after surgery compared to those without hyperpolypharmacy.
This is the authors' abstract. We don't add key points for this paper.
AIMS: Polypharmacy, hyperpolypharmacy, and potentially inappropriate medication (PIM) in older adults are growing health concerns in the aging population. Older patients with degenerative cervical myelopathy (DCM) often have multiple comorbidities and are prescribed numerous medications. Thus, we investigated the current status of medication use among older patients with DCM, identified the characteristics of those with hyperpolypharmacy, and evaluated its impact on postoperative outcomes. METHODS: This retrospective study included 130 older patients with surgery for DCM. All participants completed the Japanese Orthopaedic Association Cervical Myelopathy Evaluation Questionnaire (JOACMEQ) before and 1 year after surgery. RESULTS: Forty-two patients had hyperpolypharmacy (H group), and 88 had non-hyperpolypharmacy (N group). The commonly prescribed PIMs were antidiabetics (24.6%), nonsteroidal anti-inflammatory drugs (21.5%), and hypnotics (20.8%). Hypnotic use was significantly higher in the H group than in the N group (p < 0.001). The H group exhibited significantly more advanced frailty than the N group (p = 0.001). The preoperative JOACMEQ scores for upper extremity, lower extremity, and bladder function were significantly worse in the H group than in the N group (p = 0.020, 0.003, and 0.007, respectively) and remained significant following the multivariable model. Both groups had favorable surgical outcomes, but quality of life improvements were significant in the N group (p = 0.005) but not in the H group (p = 0.900). CONCLUSIONS: Older DCM patients with hyperpolypharmacy had more severe preoperative symptoms. Although surgery is a viable treatment option for this population, thorough preoperative informed consent regarding surgical outcomes is critically important.
Answers are grounded in this paper and cite their sources.
Hyperpolypharmacy may be linked to worse postoperative outcomes in older DCM patients; leaves open whether deprescribing improves results.
No takes yet. Share an insight, caveat, or question.
Takeda et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: